Kalaris Therapeutics Inc
kalaristx.comWhat Do They Do?
Develops an investigational drug for patients with age-related macular degeneration and other retinal diseases.
10-K for FY2025, filed Mar 17, 2026We are a clinical stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal…View ↗
We are developing TH103, a novel, clinical stage anti-vascular endothelial growth factor (“VEGF”) drug, specifically engineered to achieve…View ↗
We are currently conducting a Phase 1b/2 multiple ascending dose (“MAD”), dose-finding study evaluating four monthly loading injections of…View ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 11, 2026
−$11.5MView ↗
- ▲ +1% (Loss)
- vs −$11.4M in Q2 FY2025
-
Jul 20, 2026
Appointed a new chief financial officer
Liisa Bayko was appointed CFO and treasurer, effective July 20, 2026.
Sources
8-K, filed Jul 20, 2026
On July 16, 2026, the Board of Directors (the “Board”) of Kalaris Therapeutics, Inc. (the “Company”) appointed Liisa Bayko as Chief…View ↗
-
Apr 10, 2026
Chief financial officer Matthew Gall resigned
Gall's resignation was effective April 14, 2026.
Sources
8-K, filed Apr 10, 2026
On April 8, 2026, Matthew Gall notified Kalaris Therapeutics, Inc. (the “Company”) of his decision to resign as the Chief Financial Officer…View ↗
From cell therapies to retinal drugs
The older report centered on off-the-shelf cell therapies targeting viruses, while the latest centers on an investigational drug for neovascular and other retinal diseases.
10-K for FY2022, filed Feb 15, 2023 10-K for FY2025, filed Mar 17, 2026
Who Do They Compete With?
Competes with Roche, Novartis, Regeneron, AbbVie, Eli Lilly, Merck, Samsung Bioepis, Biogen, Coherus BioSciences, Formycon, Sandoz Group, Biocon Biologics, Amgen, Outlook Therapeutics, 4D Molecular Therapeutics, RegenexBio, Eyepoint Pharmaceuticals, Ocular Therapeutix, Kodiak Sciences, and Ollin Biosciences
10-K for FY2025, filed Mar 17, 2026In addition to the current standard of care treatments for patients with nAMD, numerous commercial and academic pre-clinical studies and…View ↗
Loading...
